Understanding the incidence and outcomes of trilateral retinoblastoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to investigate the incidence and survival rates of trilateral retinoblastoma among patients diagnosed with retinoblastoma globally. It will include data from various treatment centers over a specified period, focusing on the differences in incidence between high-income and low-income countries. The study will follow a prospective cohort design, adhering to established reporting guidelines to ensure accuracy and transparency. Data will be collected on the location of the tumors, treatment received, and survival outcomes to enhance understanding of this condition.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* patients diagnosed with retinoblastoma

Exclusion Criteria:

* none

Where it's running

• Amsterdam UMC
  Amsterdam, North Holland, Netherlands Recruiting

Study contacts

• Principal investigator: Marcus de Jong, MD PhD — Amsterdam UMC
• Study coordinator: Marcus C de Jong, MD PhD
• Email: mc.dejong@amsterdamumc.nl
• Phone: +31(0)20-4443047

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• High-dose Topotecan treatment for recurrent retinoblastoma with vitreous seeds

  This study is testing whether high-dose Topotecan can help patients with recurrent retinoblastoma and vitreous seeds keep their eye while fighting the tumor.

  Recruiting Early Phase 1 Eye & ENT Hospital of Fudan University · Shanghai, China · NCT06972602

• Linking RB1 genetic changes to eye tumors and metastasis

  We will use targeted long-read genetic sequencing on people with retinoblastoma to see if specific RB1 mutations match tumor features and the risk of spread.

  Recruiting University of Washington · Seattle, Washington · NCT06725173

• Treatment for advanced retinoblastoma using a chemoplaque

  This study is testing a new treatment using a special chemotherapy patch for young children with advanced retinoblastoma to see if it helps fight the cancer while keeping their vision safe.

  Recruiting at 2 sites Phase 2 Targeted Therapy Technologies, LLC · New York, New York and 1 other locations · NCT06679634

• New treatment for children with hard-to-treat retinoblastoma

  This study is testing a new drug for children with hard-to-treat eye cancer to see if it works better and has fewer side effects than standard chemotherapy.

  Recruiting Early Phase 1 Eye & ENT Hospital of Fudan University · Shanghai · NCT06424301

• Chemotherapy for high-risk retinoblastoma after eye removal

  This study is testing if giving chemotherapy after removing the eye can help prevent high-risk retinoblastoma from coming back in children with Stage I disease.

  Recruiting Phase 3 Sun Yat-sen University · Guangzhou, Guangdong · NCT05080010

• Collecting and analyzing eye fluid from children with retinoblastoma

  This study is trying to see if collecting eye fluid from children with retinoblastoma can help find important markers for better treatment and understanding of the disease.

  Recruiting at 9 sites Children's Hospital Los Angeles · Phoenix, Arizona and 8 other locations · NCT04959097

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.